Clinical Trial Recruitment Advertising in Singapore: IRB Approval, Payment Wording and Platform Rules

Last updated 9 October 2026 — by Adrian Tan, SDM. Marketing guidance, not legal advice. Regulation and section numbers refer to the versions on Singapore Statutes Online as at October 2026, and IRB rules to the guidelines cited. Your own IRB’s approved wording always wins; check with it, HSA or a lawyer before relying on any point.

Clinical trials in Singapore need participants, and increasingly they find them the way every other organisation finds customers: Facebook posts, Instagram stories, Google search ads, MRT posters, WhatsApp broadcasts and landing pages with an eligibility quiz. Sponsors, contract research organisations and hospital research units now ask marketing agencies to “fill the study”, often on a tight enrolment deadline.

That brief is unlike any other in healthcare marketing. In most sectors an advertiser writes the copy, checks it against the law and publishes it. In clinical research, the advertisement itself is a regulated research document. It must be approved by an institutional review board (IRB) before anyone sees it, and the words that make ordinary ads work, such as “free”, “new”, “safe”, “effective” and a bold dollar figure, are exactly the ones the review boards strike out.

This guide sets out where those rules come from, what Singapore’s main review boards allow a recruitment ad to say, how to talk about payment, and what Google, Meta and the PDPA add once the campaign goes online.

The rules at a glance

Where the rules come from

No Singapore statute contains a chapter called “clinical trial advertising”. Instead, the rules sit in three layers that a marketer has to read together.

Layer 1: the trial regulations and the Human Biomedical Research Act

Which law governs a study depends on what is being tested. The Health Products (Clinical Trials) Regulations 2016 cover trials of therapeutic products (medicines in the ordinary sense) and certain cell, tissue and gene therapy products. The Medicines (Clinical Trials) Regulations 2016 cover medicinal products tested under the Medicines Act route, for example a Chinese proprietary medicine or a supplement being tested to treat or prevent disease. Medical-device trials and observational studies fall under the Human Biomedical Research Act 2015 (HBRA), which MOH administers.

None of these instruments uses the word “advertisement” for trial recruitment. What they contain is more important: rules about how people are persuaded to take part.

• Reg 20 of both sets of trial regulations, headed “Coercion”, says no person may “by coercion, intimidation, deception or misrepresentation, cause, compel or induce” anyone to become or remain a trial subject, or to give or not withdraw consent. Under the Health Products regulations, breaching reg 20 carries a fine of up to S$20,000, up to 12 months’ jail, or both (reg 29). Under the Medicines regulations the penalty is up to S$5,000 and/or up to two years (reg 28(2)).
• HBRA s 26(1) makes it an offence to compel participation by coercion or intimidation, or to cause participation or consent by deception or misrepresentation. The penalty is up to S$100,000, up to 10 years’ jail, or both.
• HBRA s 22(2)(b) says research may not be conducted unless an IRB has approved it (or exempted it), with penalties of up to S$50,000 and/or five years under s 22(6).

A recruitment ad is the first thing a potential participant reads about a study. If it overstates benefits or plays down risk, and someone joins because of it, the ad is the obvious evidence of misrepresentation. That is why the review boards treat ad copy so strictly.

Layer 2: the IRB

Every trial needs IRB approval of its conduct (HP(CT)R reg 7(2); HBRA s 22). In Singapore the main boards are SingHealth’s Centralised IRB (CIRB), NHG Health’s Domain Specific Review Board (DSRB), and the university boards at NUS and NTU. A mutual-recognition arrangement between A*STAR IRB, SingHealth CIRB, NHG DSRB, NTU-IRB and NUS-IRB means a multi-site study needs review by only one of them.

The boards’ written guidelines on recruitment advertisements are where the practical rules live. They are not statutes, but approval is a legal precondition for the study, so ignoring them is not an option.

Layer 3: Good Clinical Practice

HSA implemented the Principles and Annex 1 of the international Good Clinical Practice guideline, ICH E6(R3), from 1 January 2026, with Annex 2 following on 1 January 2027. E6(R3) lists “advertisement for participant recruitment (if used) and information on the recruitment process” among the documents the IRB receives (1.2.2(e)), and requires the investigator to hold dated IRB approval of “participant recruitment procedures (e.g., advertisements)” before the trial starts (2.4.2). It also says payment to participants must not be coercive or an undue influence and should be “timely, prorated and not wholly contingent on completion” (1.2.8).

One point surprises many sponsors: HSA does not review recruitment ads. Its guidance on clinical trial applications lists “Clinical Trial Advertisements” among documents sponsors are not required to submit. The approval that matters is the IRB’s.

What counts as a recruitment ad

The SingHealth CIRB guideline defines direct advertising broadly: newspaper ads, posters, flyers, brochures, emails, social media posts and invitation letters. Importantly, the board reviews the ad and its caption, so the text you type above a Facebook or Instagram image is part of the approved material. A community manager who rewrites a caption to make it more engaging has, in effect, published an unapproved ad.

Three things are exempt from IRB approval under both the CIRB and NHG DSRB guidance:

• letters to doctors inviting referrals;
• news stories about the research project;
• basic trial listings on research websites, such as a registry entry that gives the title, purpose, eligibility, location and contact.

What a recruitment ad may say

The SingHealth CIRB, NHG DSRB and NTU-IRB guidelines broadly agree. An ad should use simple language and contain only what a reader needs to decide whether they are eligible and interested.

What to include

• That it is research. CIRB requires the ad to state that the study is research and, where relevant, that it involves an investigational drug or device. NHG DSRB requires a statement that volunteers are being recruited for research.
• Who is running it. The principal investigator’s name or the institution’s name and address. NTU-IRB also requires the NTU logo, the research title, the PI’s name, NTU-IRB’s contact details and the IRB reference number.
• The condition or purpose of the study.
• A summary of the eligibility criteria, so people who clearly do not qualify do not respond.
• What taking part involves: procedures, the time commitment and the location.
• A contact for further information.
• Benefits, if any, without overstating them. NHG DSRB gives a “no-cost health examination” as an example of a benefit that may be described.
• For studies recruiting minors, NTU-IRB requires a statement about parental consent.

What to leave out

The CIRB guideline lists claims that an ad must not make. NHG DSRB’s list is the same in substance:

CIRB also bars exculpatory language (wording that suggests participants give up their rights) and claims inconsistent with the product’s approved labelling.

For a marketer, the most useful way to think about this list is that the ad may describe the study, but not its expected result. A clinical trial exists because nobody yet knows whether the product works or is safe enough. Copy that implies otherwise is not just against IRB policy; it is the kind of misrepresentation reg 20 and HBRA s 26 are aimed at.

How to talk about payment

Payment is the area where ordinary performance-marketing instincts are most dangerous. In a consumer campaign, putting “Earn S$500” in large type is how you lift click-through. In trial recruitment it is specifically prohibited.

• CIRB: payment may be mentioned, but must not be emphasised with bold or enlarged print, and “the amount should not be included”.
• NHG DSRB: payment may be mentioned but not emphasised, and the ad should not state the amount.
• NTU-IRB: payment may be mentioned, but neither the payment nor its amount may be emphasised.

Behind the ad rule is a principle about what payment is for. NHG DSRB describes payment as reimbursement for time, inconvenience and expenses rather than a benefit of taking part. It must not be an undue influence, should be timely and pro-rated, and should not be wholly dependent on completing the study; a small completion incentive is acceptable. ICH E6(R3) says the same, adding that reasonable reimbursement of travel and lodging is not coercive. The Bioethics Advisory Committee’s guidelines put it as “any payment in addition to expenses incurred, should not amount to an inducement”.

Two further rules matter to anyone designing the funnel:

• No recruitment bonuses or referral payments. NHG DSRB does not permit payments for referring a subject or sponsor payments tied to the rate or timing of recruitment. A “refer a friend, get S$50” mechanic, standard in consumer marketing, does not belong in a trial campaign.
• Tissue and biobank studies. HBRA s 32 bans commercial trading in human tissue, and s 33 makes it an offence to issue any advertisement for buying or selling human tissue, with penalties of up to S$100,000 and/or 10 years. Reimbursing expenses is allowed (s 32(4)), but an ad for a tissue-donation or biobank study must never read as an offer to pay for samples.

Worked example: rewriting a Facebook recruitment post

Imagine a sponsor sends this draft for a study of an investigational asthma inhaler:

“BREATHE EASIER! Try a new asthma treatment for FREE and get paid S$600. Safe, doctor-approved, limited slots. Sign up now!”

Almost every phrase is a problem. “Breathe easier” implies a favourable outcome. “New asthma treatment” without “investigational” is banned. “FREE” is banned outright by NTU-IRB and as “free medical treatment” by CIRB. “Paid S$600” states and emphasises the amount. “Safe” and “doctor-approved” claim safety and imply endorsement. “Limited slots” adds urgency, which sits badly with the voluntary-participation principle in reg 19(1)(m).

An approvable version might read:

“Research study for adults with asthma. [Institution] is recruiting adults aged 21 to 65 with asthma for a research study of an investigational inhaler. The study involves six clinic visits over 12 weeks at [location]. Participants will be reimbursed for their time and travel. To find out if you are eligible, contact [name] at [phone/email]. [IRB name and reference number, if required.]”

It is plainer, and it will probably produce fewer clicks per impression. But the people who respond are better informed and more likely to be eligible, which is what actually fills a study, and it can be published without putting the investigator’s approval at risk.

Running recruitment on Google, Meta and other channels

Google Ads

Google does not allow clinical trial recruitment ads in most countries, but Singapore is on its allowed list. Even where allowed, ads cannot promote prescription drugs, cannot set unrealistic expectations of the product being tested, and cannot suggest it is safe. If an ad is disapproved for lacking healthcare approval, the route is to apply for Google’s healthcare and medicines approval for that location. Those limits line up closely with the IRB rules, so copy written to IRB standards will usually pass Google’s review too.

Meta (Facebook and Instagram)

Meta has no clinical-trial-specific policy we could verify for Singapore, but three of its general rules shape every recruitment campaign:

• Personal attributes. Ad copy must not assert or imply that the viewer has a medical condition. “Do you have diabetes?” or “Living with psoriasis?” addressed to the viewer is the classic rejection. Describe the study instead: “A research study for adults with type 2 diabetes”.
• Lead forms. Meta’s Advertising Standards prohibit lead-ad questions asking for health information, including physical or mental health, medical treatments, conditions or disabilities, without Meta’s prior written permission. Send people to a landing page you control for pre-screening instead.
• Targeting. Meta removed detailed targeting options based on health causes and conditions from 19 January 2022. Recruitment campaigns now rely on location, age and gender, custom audiences built from engagement or consented lists, and lookalikes.

Health and wellness products must also be targeted at people aged 18 and over. Remember too that under the trial regulations a “minor” is someone under 21 who has never married, so a study for adults may need an age floor above Meta’s.

Translations

NHG DSRB has not required separate approval of translated posters and flyers since 19 October 2020, but the principal investigator is responsible for their accuracy. Singapore campaigns often run in Chinese, Malay and Tamil, so budget for a professional translation checked against the approved English.

Pre-screening forms and the PDPA

Most digital recruitment funnels end in a pre-screening questionnaire: age, diagnosis, current medication, perhaps a few clinical questions, then contact details. That form collects health data, and the Personal Data Protection Act applies to it.

• Get consent and say why. The PDPA’s research exception lets organisations use personal data without consent only in narrow circumstances, for example where identifiable data is needed and there is a clear public benefit. A recruiter collecting fresh data from the public through a lead form will not usually fit those conditions, so tell people what you are collecting, for what purpose and who will see it, and get their consent.
• Do not ask for NRIC numbers. PDPC’s NRIC guidelines, applied since 1 September 2019, say organisations generally may not collect NRIC numbers unless the law requires it, an exception applies or a high degree of identity verification is needed. A pre-screening form needs none of those. The same care applies to FIN, birth certificate and work permit numbers.
• Do not reuse the list for marketing. PDPC’s healthcare-sector guidelines say consent cannot be deemed for purposes unrelated to the person’s care, and organisations cannot rely on the legitimate interests exception to send direct marketing. Someone who answered a trial questionnaire has not agreed to receive a clinic’s promotions.
• Get the form approved too. The questionnaire is part of the recruitment process the IRB reviews under ICH E6(R3) 1.2.2, so submit it with the ad.

Breaches of the PDPA’s main obligations can attract financial penalties of up to 10% of Singapore turnover for organisations with turnover above S$10 million, or up to S$1 million otherwise (s 48J). Our guide to PDPA rules for marketing tracking in Singapore covers pixels and consent on landing pages in more detail.

A checklist for agencies running trial recruitment

1. Identify the regime and the IRB before writing a word. Ask the sponsor which regulations apply and which board approved the protocol.
2. Get the board’s own guideline. CIRB, DSRB, NTU-IRB and NUS-IRB each publish their own; NUS’s are available to NUS researchers or on request from the board.
3. Write every asset as a submission: each headline, body, caption, image, landing page and form. Variants for A/B testing must each be approved.
4. Remove amounts, superlatives and outcome claims, and keep “investigational” next to any product description.
5. Plan the media calendar around approval time, and lock copy once approved. Any later change goes back to the IRB.
6. Build the funnel to respect the platforms: no medical questions on Meta lead forms, no “you have [condition]” copy, a consented landing page for pre-screening.
7. Keep records. ICH E6(R3) treats recruitment ads as essential trial records, so the investigator will need the exact versions that ran and where.
8. Report leads, not just clicks. The metric that matters is eligible, consented participants, which is a reason to measure the funnel end to end rather than optimise for cheap form fills.

Conclusion

Clinical trial recruitment is one of the few kinds of advertising in Singapore where every word needs approval before publication. The trial regulations and the Human Biomedical Research Act make misleading people into a study an offence; the review boards turn that into concrete rules about payment, benefits and claims; and Google, Meta and the PDPA add their own limits once the campaign goes online. Ads that describe the study plainly, mention reimbursement without amounts and avoid any promise of results can be approved quickly and run with confidence.

If you are planning a recruitment campaign and want media and funnels built around those constraints, that is the kind of work our performance marketing team in Singapore does; see our client case studies for results. For the wider regulatory picture in healthcare, read our guides to health product advertising rules in Singapore, digital marketing for healthcare providers and allied health advertising, and check our website legal requirements checklist before building the landing page. For the bigger picture, start with our complete guide to performance marketing in Singapore.

Frequently asked questions

Does a clinical trial ad need approval in Singapore?

Yes. Recruitment ads, posters, social posts and their captions must be approved by the IRB overseeing the study before they are used, under the guidelines of boards such as SingHealth CIRB and NHG DSRB. HSA does not review recruitment ads; the IRB’s approval is what matters.

Can a recruitment ad say how much participants will be paid?

No. SingHealth CIRB and NHG DSRB allow an ad to mention that participants will be paid or reimbursed, but not the amount, and payment must not be emphasised with bold or enlarged type. Payment is treated as reimbursement for time and expenses, not a benefit.

Can I describe the study drug as a new treatment?

Only if the ad explains that it is investigational. Review boards ban “new treatment”, “new drug” or “new medication” on their own, and also ban claims that the product is safe, effective, or equivalent or superior to other products.

Is it illegal to mislead people into joining a clinical trial?

Yes. Inducing someone to take part or consent by deception or misrepresentation is an offence under reg 20 of the clinical trials regulations (up to S$20,000 and/or 12 months under the Health Products version) and under section 26 of the Human Biomedical Research Act (up to S$100,000 and/or 10 years).

Can I run clinical trial recruitment ads on Google and Facebook?

Yes, with limits. Singapore is on Google’s list of countries where trial recruitment ads are allowed, provided they do not promote prescription drugs or suggest the product is safe. Meta bans copy implying the viewer has a medical condition and lead-form questions about health without its written permission.

Can a pre-screening form ask for NRIC numbers?

It should not. PDPC’s NRIC guidelines say organisations generally may not collect NRIC numbers unless the law requires it or a high degree of identity verification is needed. Collect only what you need to check eligibility, with clear consent for that purpose.